BLI5100

DRUG3 trials

Sponsors

Braintree Laboratories

Conditions

Erosive EsophagitisNon-erosive Reflux Disease

Phase 3

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

CompletedNCT05587322

Braintree LaboratoriesNon-erosive Reflux Disease

Start: 2022-09-06End: 2024-04-23Updated: 2024-07-24

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

CompletedNCT05587309

Braintree LaboratoriesErosive Esophagitis

Start: 2022-10-30End: 2025-06-16Updated: 2026-06-16

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

CompletedNCT05890001

Braintree LaboratoriesErosive Esophagitis, Non-erosive Reflux Disease

Start: 2023-04-05End: 2024-10-08Updated: 2025-09-26